Evidence map›Paper›PMID 35710783›Full record

ArticleScientific reports2022

Amyloid-β impairs mitochondrial dynamics and autophagy in Alzheimer's disease experimental models.

Macarena de la Cueva, Desiree Antequera, Lara Ordoñez-Gutierrez, Francisco Wandosell, Antonio Camins, Eva Carro, Fernando Bartolome

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Mitochondrial NMNAT3 reduces amyloid aggregates inMitochondrial communications · 2026
    Article
  11. Article
  12. Article
  13. Review
  14. The connection between autophagy and Alzheimer's disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Review
  15. Review
  16. Article
  17. Boosting Neurogenesis as a Strategy in Treating Alzheimer's Disease.International journal of molecular sciences · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Macarena de la CuevaNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
Desiree AntequeraNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
Lara Ordoñez-GutierrezNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
Francisco WandosellNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
Antonio CaminsNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
Eva CarroNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain. carroeva@h12o.es.ORCID http://orcid.org/0000-0002-6504-4579
Fernando BartolomeNetwork Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain. fbartolome.imas12@h12o.es.ORCID http://orcid.org/0000-0001-9322-8933
Biomedical Research Networking Center on Neurodegenerative Diseases · ESResearch Institute Hospital 12 de Octubre · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most accepted hypothesis in Alzheimer's disease (AD) is the amyloid cascade which establishes that Aβ accumulation may induce the disease development. This accumulation may occur years before the clinical symptoms but it has not been elucidated if this accumulation is the cause or the consequence of AD. It is however, clear that Aβ accumulation exerts toxic effects in the cerebral cells. It is important then to investigate all possible associated events that may help to design new therapeutic strategies to defeat or ameliorate the symptoms in AD. Alterations in the mitochondrial physiology have been found in AD but it is not still clear if they could be an early event in the disease progression associated to amyloidosis or other conditions. Using APP/PS1 mice, our results support published evidence and show imbalances in the mitochondrial dynamics in the cerebral cortex and hippocampus of these mice representing very early events in the disease progression. We demonstrate in cellular models that these imbalances are consequence of Aβ accumulation that ultimately induce increased mitophagy, a mechanism which selectively removes damaged mitochondria by autophagy. Along with increased mitophagy, we also found that Aβ independently increases autophagy in APP/PS1 mice. Therefore, mitochondrial dysfunction could be an early feature in AD, associated with amyloid overload.

Indexed as

Alzheimer DiseaseAmyloidosisAmyloidAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsAutophagyDisease Models, AnimalDisease ProgressionMiceMice, TransgenicMitochondrial DynamicsModels, TheoreticalAmyloidAmyloid beta-PeptidesAmyloid beta-Protein Precursor

Identifiers

PMID35710783
PMCPMC9203760
OpenAlexW4283015188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.